The marketing partner (Eisai ESALY.PK) for Arena's (ARNA) obesity-fighting Belviq has petitioned the DEA to expedite its approval process. If granted (this sort of request is rarely denied), this could have the drug in pharmacies on February 7, writes Joe Dedvukaj. Combined with what looks to be imminent EU approval, Street analysts will find themselves needing to catch up to lofty sales figures.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs